Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of June 2026
Principal Executive Office: Level 15, 500 Collins Street, Melbourne, Victoria 3000 Australia
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. As a development stage enterprise, this report focuses on corporate governance updates rather than financial performance.
Material Changes
- Registered Office Address: The company submitted Exhibit 99.1 indicating a change of registered office address.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document serves primarily to incorporate the address change into existing Registration Statements on Form S-8 and Form F-3.
Investor Verification Checklist
- Verify the new registered office address details in Exhibit 99.1.
- Confirm the impact of the address change on the referenced Registration Statements (Files No. 333-251073, 333-248980, 333-228671, 333-274816, 333-251647, 333-231417, and 333-250076).
- Review subsequent filings for financial data, as this 6-K contains no financial statements.